Published finding — does the expert body still believe it?
The DAPA-HF trial's stated primary conclusion — Dapagliflozin reduces heart-failure worsening and CV death in HFrEF with or without diabetes. — replicates in independent cohorts.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray et al. · New England Journal of Medicine · 2019
· openalex W2974260792
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0497
The EMPEROR-Reduced trial's stated primary conclusion — Empagliflozin reduces cardiovascular death or heart-failure hospitalization in HFrEF regardless of diabetes status. — replicates in independent cohorts.
0.0843
The cardiovascular benefit of dapagliflozin in HFrEF patients is independent of the presence or absence of type 2 diabetes, suggesting glucose-independent mechanisms of action.
0.0858
Dapagliflozin 10 mg once daily reduces the composite of worsening heart failure or cardiovascular death (HR 0.74; 95% CI 0.65–0.85) compared to placebo in patients with HFrEF (EF ≤40%), regardless of diabetes status.
0.0858
Dapagliflozin reduces the risk of a first worsening heart failure event (HR 0.70; 95% CI 0.59–0.83) in patients with HFrEF compared to placebo.
0.0944
Dapagliflozin reduces cardiovascular mortality (HR 0.82; 95% CI 0.69–0.98) in patients with HFrEF compared to placebo.
0.1030
SGLT2 inhibitor class benefits observed in type 2 diabetes cardiovascular outcome trials will generalize to the broader HFrEF population, including patients without diabetes.